[vc_row][vc_column][vc_column_text]Anne Li January 26th, 2018
Screening a class of recently-developed drug compounds — so-called “CDK inhibitors” capable of blocking CDK7/12/13 proteins — against hundreds of different human cancer cell lines, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center have found that CDK12 inhibitors pack a particularly lethal punch to Ewing sarcoma, a rare cancer typically affecting children and young adults.
See original article at: https://www.sciencedaily.com/releases/2018/01/180125230343.htm
[/vc_column_text][/vc_column][/vc_row]
